OIE Reference Laboratory Reports Activities

Activities in 2021

This report has been submitted : 2022-01-13 12:59:36

Name of disease (or topic) for which you are a designated OIE Reference Laboratory:	Equine rhinopneumonitis
Address of laboratory:	108 Gluck Equine Research Center Lexington, Kentucky 40546-0099 UNITED STATES OF AMERICA
Tel.:	+1-859 218-1094
Fax:	+1-859 257 85 42
E-mail address:	ptimoney@uky.edu
Website:	
Name (including Title) of Head of Laboratory (Responsible Official):	Dr. Dan Howe (Interim)
Name (including Title and Position) of OIE Reference Expert:	Dr. Peter Timoney, Professor and Frederick Van Lennep Chair in Equine Veterinary Science
Which of the following defines your laboratory? Check all that apply:	Academic

ToR 1: To use, promote and disseminate diagnostic methods validated according to OIE Standards

1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.? (Not for quality control, proficiency testing or staff training)

Yes

Diagnostic Test	Indicated in OIE Manual (Yes/No)	Total number of test performed last year	
Indirect diagnostic tests		Nationally	Internationally
VN test	Yes	46	--
Direct diagnostic tests		Nationally	Internationally
VI attempted in RK-13 and equine endothelial cells	Yes	10	--
Real-time RT-PCR	Yes	859	--
FAT	Yes	366	--

ToR 2: To develop reference material in accordance with OIE requirements, and implement and promote the application of OIE Standards.
To store and distribute to national laboratories biological reference products and any other reagents used in the diagnosis and control of the designated pathogens or disease.

2. Did your laboratory produce or supply imported standard reference reagents officially recognised by the OIE?

No

3. Did your laboratory supply standard reference reagents (non OIE-approved) and/or other diagnostic reagents to OIE Member Countries?

No

4. Did your laboratory produce vaccines?

No

5. Did your laboratory supply vaccines to OIE Member Countries?

No

ToR 3: To develop, standardise and validate, according to OIE Standards, new procedures for diagnosis and control of the designated pathogens or diseases

6. Did your laboratory develop new diagnostic methods validated according to OIE Standards for the designated pathogen or disease?

No

7. Did your laboratory develop new vaccines according to OIE Standards for the designated pathogen or disease?

No

ToR 4: To provide diagnostic testing facilities, and, where appropriate, scientific and technical advice on disease control measures to OIE Member Countries

8. Did your laboratory carry out diagnostic testing for other OIE Member Countries?

No

9. Did your laboratory provide expert advice in technical consultancies on the request of an OIE Member Country?

Yes

Name of the OIE Member Country receiving a technical consultancy	Purpose	How the advice was provided
ITALY	Technical advice on relevance of trace element levels and clinical severity of EHV-1 disease syndromes.	Remote assistance (email)
UNITED STATES OF AMERICA	Technical advice on respective roles of EHV-1/EHV-4 in causing neurologic disease.	Remote assistance (email)
UNITED STATES OF AMERICA	Technical advice on an allelic Real-time PCR for genotyping strains of EHV-1 associated with neurologic disease.	Remote assistance (email)
UNITED STATES OF AMERICA	Technical advice on epidemiology, prevention and control of EHV-1 related disease.	Remote assistance (email)
ITALY	Technical advice on meta-analysis of trials evaluating the efficacy of vaccination against EHV-1 related diseases.	Remote assistance (email)
UNITED STATES OF AMERICA	Advice on the pathogenesis of EHV-1 mediated neurologic disease.	Remote assistance (email)

ToR 5: To carry out and/or coordinate scientific and technical studies in collaboration with other laboratories, centres or organisations

10. Did your laboratory participate in international scientific studies in collaboration with OIE Member Countries other than the own?

No

ToR 6: To collect, process, analyse, publish and disseminate epizootiological data relevant to the designated pathogens or diseases

11. Did your Laboratory collect epizootiological data relevant to international disease control?

Yes

If the answer is yes, please provide details of the data collected:
The laboratory collected epidemiological data relevant to EHV-1 related abortions and equine myeloencephalopathy in the USA with particular reference to the effectiveness of vaccination programs where these were carried out for the prevention and control of these diseases. Such data were compared with the outcome of analogous studies into the incidence of those manifestations of EHV-1 infection in other countries, where this information is available.

12. Did your laboratory disseminate epizootiological data that had been processed and analysed?

No

If the answer is no, please provide a brief explanation of the situation:
This is pending analysis of the data for the entire year 2021.

13. What method of dissemination of information is most often used by your laboratory? (Indicate in the appropriate box the number by category)

a) Articles published in peer-reviewed journals: 0

b) International conferences: 0

c) National conferences: 1
Annual meeting of the Committee on Equine at the 2021 Conference (Virtual) of the USAHA.

d) Other:
(Provide website address or link to appropriate information) 0

ToR 7: To provide scientific and technical training for personnel from OIE Member Countries
To recommend the prescribed and alternative tests or vaccines as OIE Standards

14. Did your laboratory provide scientific and technical training to laboratory personnel from other OIE Member Countries?

No

ToR 8: To maintain a system of quality assurance, biosafety and biosecurity relevant for the pathogen and the disease concerned

15. Does your laboratory have a Quality Management System?

No

Explain Quality Management System in adoption process or currently in place
While the Quality Management System in the OIE Reference Laboratory is not externally accredited, it has measured up to the requirements for accreditation according to ISO 17025 for several years. As stated in previous annual reports to the OIE, the laboratory is not in a financial position to afford the cost of certification by an external accreditation company. It should be emphasised that any agent detection/antibody determination test that was undertaken in 2021 was carried out at the University of Kentucky Veterinary Diagnostic Laboratory (UKVDL), the primary service arm of the Department of Veterinary Science. The UKVDL has a Quality Management program in place that is annually accredited by the American Association of Veterinary Laboratory Diagnosticians and meets the standards of ISO 17025.

16. Is your quality management system accredited?

No

17. Does your laboratory maintain a “biorisk management system” for the pathogen and the disease concerned?

Yes

(See Manual of Diagnostic Tests and Vaccines for Terrestrial Animals, Chapter 1.1.4)

ToR 9: To organise and participate in scientific meetings on behalf of the OIE

18. Did your laboratory organise scientific meetings on behalf of the OIE?

No

19. Did your laboratory participate in scientific meetings on behalf of the OIE?

Yes

Title of event	Date (mm/yy)	Location	Role (speaker, presenting poster, short communications)	Title of the work presented
Committee on Equine Annual Conference of USAHA	10/21	Virtual meeting	Participant	Review of incidence of EHM 2019-2021.

ToR 10: To establish and maintain a network with other OIE Reference Laboratories designated for the same pathogen or disease and organise regular inter-laboratory proficiency testing to ensure comparability of results

20. Did your laboratory exchange information with other OIE Reference Laboratories designated for the same pathogen or disease?

No

21. Was your laboratory involved in maintaining a network with OIE Reference Laboratories designated for the same pathogen or disease by organising or participating in proficiency tests?

No

22. Did your laboratory collaborate with other OIE Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest?

No

ToR 11: To organise inter-laboratory proficiency testing with laboratories other than OIE Reference Laboratories for the same pathogens and diseases to ensure equivalence of results

23. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than OIE Reference Laboratories for the same disease?

No

Note: See Interlaboratory test comparisons in: Laboratory Proficiency Testing at: http://www.oie.int/en/our-scientific-expertise/reference-laboratories/proficiency-testing see point 1.3

ToR 12: To place expert consultants at the disposal of the OIE

24. Did your laboratory place expert consultants at the disposal of the OIE?

Yes

Kind of consultancy	Location	Subject (facultative)
Review and edit selected Code Chapters	Remote assistance (e-mail)	Diseases, Infections and Infestations listed by the OIE, Infection with Taylorella equigenitalis (Contagious Equine Metritis), Infection with Theileria equi & Babesia caballi (equine piroplasmosis).
Chair, ad hoc group of experts tasked with redrafting Code Chapters	Remote consultation (e-mail & phone)	Revision of Chapter on Equine Piroplasmosis
Chair, ad hoc group of experts tasked with redrafting Code Chapters	Remote consultation (e-mail & phone)	Revision of Chapter on Contagious Equine Metritis
Revision of Manual Chapter on Equine Viral Arteritis in progress	Remote assistance (e-mail)	Manual Chapter on Equine Viral Arteritis

25. Additional comments regarding your report: